Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OMOP May Seek To Partner With Mini-Sentinel On Drug Safety, PCORI On Outcomes Research

Executive Summary

The drug industry-funded Observational Medical Outcomes Partnership may seek collaboration with high-profile public-private drug safety and comparative effectiveness research initiatives.

You may also be interested in...



PCORI Critics Emerge As Institute Formally Releases Draft Methods Report

As the Patient-Centered Outcomes Research Institute opens up the public comment period for the draft report created by the institute’s Methodology Committee, criticisms on the direction PCORI is moving are beginning to surface, including accusations that it is becoming just another AHRQ or NIH.

Mini Sentinel Data Covers 126 Million Patients; FDA Weighing Potential Uses For Drug Industry

With the recent addition of claims data from two major insurance companies, the FDA postmarketing drug safety surveillance pilot project known as Mini Sentinel has already exceeded its statutory goal of gaining access to electronic health care data for 100 million individuals by July 12, 2012.

Bridge Too Far? BMS Launch Plan For Sotyktu Pressured By Prospect Of Medicare Price Controls

With price controls in Medicare looming nine years after approval, launch strategies such as ‘bridge’ programs that build initial volume with free drug may have to be adjusted.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS054711

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel